TY  - JOUR

T1  - Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.

JO  - Journal of Clinical Oncology

PY  - 2022/02/20

AU  - Hussain SA

AU  - Qureshi M

AU  - Tahir B

AU  - Rehan A

AU  - Catto JWF

ED  - 

DO  - DOI: 10.1200/jco.2022.40.6_suppl.461

PB  - American Society of Clinical Oncology (ASCO)

VL  - 40

IS  - 6_suppl

SP  - 461

EP  - 461

Y2  - 2024/12/22

ER  -